197 related articles for article (PubMed ID: 2108076)
1. Bismuth subsalicylate reduces peptic injury of the oesophagus in rabbits.
Tay HP; Chaparala RC; Harmon JW; Huesken J; Saini N; Hakki FZ; Schweitzer EJ
Gut; 1990 Jan; 31(1):11-6. PubMed ID: 2108076
[TBL] [Abstract][Full Text] [Related]
2. Aspirin renders the oesophageal mucosa more permeable to acid and pepsin.
Lanas AI; Sousa FL; Ortego J; Esteva F; Blas JM; Soria J; Sáinz R
Eur J Gastroenterol Hepatol; 1995 Nov; 7(11):1065-72. PubMed ID: 8680906
[TBL] [Abstract][Full Text] [Related]
3. Cytoprotective effect of bismuth subsalicylate in indomethacin-treated rats is associated with enhanced mucus bismuth concentration.
Tanaka S; Guth PH; Carryl OR; Kaunitz JD
Aliment Pharmacol Ther; 1997 Jun; 11(3):605-12. PubMed ID: 9218090
[TBL] [Abstract][Full Text] [Related]
4. Acute and chronic stress-induced oxidative gastrointestinal mucosal injury in rats and protection by bismuth subsalicylate.
Bagchi D; Carryl OR; Tran MX; Bagchi M; Garg A; Milnes MM; Williams CB; Balmoori J; Bagchi DJ; Mitra S; Stohs SJ
Mol Cell Biochem; 1999 Jun; 196(1-2):109-16. PubMed ID: 10448909
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea.
DuPont HL; Flores Sanchez J; Ericsson CD; Mendiola Gomez J; DuPont MW; Cruz Luna A; Mathewson JJ
Am J Med; 1990 Jun; 88(6A):15S-19S. PubMed ID: 2192553
[TBL] [Abstract][Full Text] [Related]
6. The gastroduodenal mucus barrier and its role in protection against luminal pepsins: the effect of 16,16 dimethyl prostaglandin E2, carbopol-polyacrylate, sucralfate and bismuth subsalicylate.
Copeman M; Matuz J; Leonard AJ; Pearson JP; Dettmar PW; Allen A
J Gastroenterol Hepatol; 1994; 9 Suppl 1():S55-9. PubMed ID: 7881020
[TBL] [Abstract][Full Text] [Related]
7. Sucralfate prevents experimental peptic esophagitis in rabbits.
Schweitzer EJ; Bass BL; Johnson LF; Harmon JW
Gastroenterology; 1985 Mar; 88(3):611-9. PubMed ID: 3917956
[TBL] [Abstract][Full Text] [Related]
8. Alkaline esophagitis: a comparison of the ability of components of gastroduodenal contents to injure the rabbit esophagus.
Lillemoe KD; Johnson LF; Harmon JW
Gastroenterology; 1983 Sep; 85(3):621-8. PubMed ID: 6307806
[TBL] [Abstract][Full Text] [Related]
9. Bismuth subsalicylate in the treatment of H2 blocker resistant duodenal ulcers: role of Helicobacter pylori.
Wagner S; Gebel M; Haruma K; Bär W; Lange P; Freise J; Gladziwa U; Schmidt FW
Gut; 1992 Feb; 33(2):179-83. PubMed ID: 1347278
[TBL] [Abstract][Full Text] [Related]
10. Prevention of diarrhea caused by enterotoxigenic Escherichia coli: lessons learned with volunteers.
Graham DY; Evans DG
Rev Infect Dis; 1990; 12 Suppl 1():S68-72. PubMed ID: 2406859
[TBL] [Abstract][Full Text] [Related]
11. Bismuth subsalicylate--an aid to the diagnosis and treatment of reflux esophagitis.
Bernstein RK
Diabetes Care; 1984; 7(4):404-5. PubMed ID: 6468241
[No Abstract] [Full Text] [Related]
12. Systematic Review and Meta-Analyses Assessment of the Clinical Efficacy of Bismuth Subsalicylate for Prevention and Treatment of Infectious Diarrhea.
Brum JM; Gibb RD; Ramsey DL; Balan G; Yacyshyn BR
Dig Dis Sci; 2021 Jul; 66(7):2323-2335. PubMed ID: 32772204
[TBL] [Abstract][Full Text] [Related]
13. Inadvertent exaggerated anticoagulation following use of bismuth subsalicylate in an enterally fed patient receiving warfarin therapy.
Bingham AL; Brown RO; Dickerson RN
Nutr Clin Pract; 2013 Dec; 28(6):766-9. PubMed ID: 24163322
[TBL] [Abstract][Full Text] [Related]
14. Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers.
Graham DY; Estes MK; Gentry LO
Gastroenterology; 1983 Nov; 85(5):1017-22. PubMed ID: 6352386
[TBL] [Abstract][Full Text] [Related]
15. Superoxide anions produced by inflammatory cells play an important part in the pathogenesis of acid and pepsin induced oesophagitis in rabbits.
Naya MJ; Pereboom D; Ortego J; Alda JO; Lanas A
Gut; 1997 Feb; 40(2):175-81. PubMed ID: 9071927
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology of gastrointestinal infections: the role of bismuth subsalicylate. Scottsdale, Arizona, 11-14 February 1988. Proceedings.
Rev Infect Dis; 1990; 12 Suppl 1():S1-119. PubMed ID: 2305172
[No Abstract] [Full Text] [Related]
17. Prevention of travelers' diarrhea by the tablet formulation of bismuth subsalicylate.
DuPont HL; Ericsson CD; Johnson PC; Bitsura JA; DuPont MW; de la Cabada FJ
JAMA; 1987 Mar; 257(10):1347-50. PubMed ID: 3820443
[TBL] [Abstract][Full Text] [Related]
18. Bismuth subsalicylate in the prevention of colonization of infant mice with Campylobacter jejuni.
Hänninen ML
Epidemiol Infect; 1990 Jun; 104(3):397-404. PubMed ID: 2347383
[TBL] [Abstract][Full Text] [Related]
19. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
Chey WD; Fisher L; Elta GH; Barnett JL; Nostrant T; DelValle J; Hasler WL; Scheiman JM
Am J Gastroenterol; 1997 Sep; 92(9):1483-6. PubMed ID: 9317068
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of bismuth subsalicylate in relieving symptoms of indigestion.
Hailey FJ; Newsom JH
Arch Intern Med; 1984 Feb; 144(2):269-72. PubMed ID: 6365007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
